PODXL and neoplasm: These results, in combination with our previous demonstration of the presence of this epitope only on a tumor-glycoform of PODXL, suggest that the PODO447 epitope is an excellent candidate for targeted cancer immunotherapies such as CAR T cells, T cell engagers or ADC.